Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
For: Relapsed or refractory precursor B-cell acute lymphoblastic leukemia and lymphoma
A Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy and of Natural Killer Cell Transplantation Versus Conventional Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
For: acute myeloid leukemia (AML)
Phase I Study of Bevacizumab and Sorafenib Combined with Low Dose Cyclophosphamide in Patients with Refractory Solid Tumors and Leukemia
For: Recurrent or refractory solid tumors and leukemias
A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) with and without Natural Killer Cells to Chemotherapy in Children and Adolescents with Recurrent/Refractory Neuroblastoma
For: Recurrent / refractory neuroblastoma
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus NK Cell Transplantation in Patients with Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
For: Relapsed or refractory hematologic malignancies
A Reduced Intensity Conditioning Regimen with CD3-Depleted Hematopietic Stem Cells to Improve Survival for Patients with Hematologic Malignancies Undergoing Haploidentical Stem Cell Transplantation
For: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Paroxysmal Nocturnal Hemoglobinuria (PNH), Hodgkin lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome (MDS)
Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma
For: Hodgkin lymphoma
First International Inter-Group Study for Nodular Lymphocyte Predominant Hodgkin's Lymphoma in Children and Adolescents
For: Lymphocyte predominant Hodgkin lymphoma
HLA - Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less than 2 Years of Age with Hematologic Malignancies
For: Leukemias (high risk hematologic malignancies)
International Pediatric Adrenocortical Tumor Registry Data Collection
For: adrenocortical carcinoma
A Pilot Feasibility Study of Gene Transfer for X-linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells
For: X-linked Severe Combined Immunodeficiency (SCID-X1)
A Phase II Study Of Intensity Modulated Radiation Therapy (IMRT) In High-Risk Abdominal Neuroblastoma
For: High risk abdominal neuroblastoma
Study for Newly Diagnosed patients with Acute Lymphoblastic Lymphoma
For: Acute lymphoblastic leukemia
Pilot Study of Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
For: Acute lymphoblastic leukemia (ALL)
Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies and Solid Tumors
For: Refractory or relapsed leukemia (AML, T-ALL, CML, JMML), T-cell lymphoma, myelodysplastic syndrome, Ewing sarcoma (ESFT), rhabdomyosarcoma (RMS)
A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children with Relapsed or Refractory Solid Tumors or Lymphomas
For: Relapsed or refractory solid tumors or lymphomas
A Pilot Pharmacokinetic, Pharmacodynamic, and Feasibility Study of Sorafenib in Combination with Cytarabine and Clofarabine in Patients with Refractory or Relapsed Hematologic Malignancies
For: Acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia (ALL), infantile leukemia (both AML and ALL), AML w/prior myelodysplastic syndrome (MDS), myelodysplastic / myeloproliferative neoplasms, biphenotypic leukemia
A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma after Radical Resection
For: Craniopharyngioma
Image Guided Radiotherapy for the Treatment of Musculoskeletal Tumors: A Phase II Prospective Evaluation of Radiation-related Treatment Effects
For: Ewing sarcoma; rhabdomyosarcoma; primitive neuroectodermal tumors (PNET) of the musculoskeletal system; soft tissue sarcomas; other bone sarcomas; chordoma
A Phase I trial of the humanized anti-GD2 antibody (hu12.18K322A) in children and adolescents with neuroblastoma, osteosarcoma and melanoma
For: Neuroblastoma, osteosarcoma and melanoma
Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants with Diffuse Intrinsic Pontine Glioma and High-Grade Glioma
For: Progressive or recurrent pontine glioma or high-grade glioma
Phase I Study of Platelet Derived Growth Factor Receptor (PDGFR) Inhibitor Crenolanib in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent High-Grade Glioma Including Diffuse Intrinsic Pontine Glioma
For: Newly diagnosed diffuse Intrinsic Pontine glioma and recurrent / progressive high grade glioma including diffuse intrinsic pontine glioma
A Phase I Study of 5-Fluorouracil In Children And Young Adults With Recurrent Ependymoma
For: Recurrent ependymoma
Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma or Ependymoma
For: Embryonal brain tumors, choroid plexus carcinoma or ependymoma
Total Therapy Study XVI for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia
For: Acute Lymphoblastic Leukemia
Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen
For: High risk hematologic malignancies
Non St. Jude Protocols
A Phase I dose escalation study of REOLYSIN, a replication competent reovirus, in pediatric patients with relapsed or refractory solid tumors
For: Recurrent solid tumors
A Phase I Study Of The C-Met Inhibitor Tivantinib (ARQ 197, IND#112603) In Children With Relapsed or Refractory Solid Tumors (ADVL1111)
For: Relapsed or refractory solid tumors or brain tumors
A Phase I Study of AMG 386 (IND#114215), An Angiopoietin Neutralizing Peptibody, In Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors (ADVL1115)
For: Relapsed or refractory solid tumors, including CNS tumors
A Phase I Study of XL184 (Cabozantinib, IND# 116059) In Children and Adolescents with Recurrent or Refractory Solid Tumors, Including CNS Tumors (ADVL1211)
For: Recurrent or refractory solid tumors, including CNS tumors
A Phase I Dose Escalation Study of Seneca Valley Virus (NTX-010), a Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients with Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors with Neuroendocrine Features
For: Neuroblastoma, rhabdomyosarcoma, Wilms tumor, retinoblastoma, adrenocortical carcinoma and carcinoid tumor
A Phase I/II Study of PF-02341066, An Oral Small Molecule Inhibitor Of Anaplastic Lymphoma Kinase (ALK) And C-Met, In Children With Relapsed/Refractory Solid Tumors And Anaplastic Large Cell Lymphoma
For: Relapses/refractory solid tumors and anaplastic large cell lymphoma
A Phase II Study of MLN8237 (IND#102984), A Selective Aurora Kinase Inhibitor, In Children with Recurrent/Refractory Solid Tumors and Leukemias (ADVL0921)
For: recurrent or refractory solid tumors (including rhabdoid and malignant germ cell tumors of the CNS) and leukemias
A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
For: Relapsed or refractory B-precursor acute lymphoblastic leukemia
Killer Immunoglobulin-Like Receptor (KIR) Incompatible Hematopoietic Cell Transplantation (HCT) for Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children’s Oncology Group (COG) Study (AAML05P1)
For: Refractory and relapsed acute myelogenous leukemia (AML)
A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Tumor (SCUSF 0901; ACCL0922) Site CTEP ID= TN024
For: Previously treated brain tumors
A phase I, multi-center, dose escalation study of CAT-8015 in children, adolescents and young adults with refractory CD22+ acute lymphoblastic leukemia (ALL), or non-Hodgkin’s Lymphoma (NHL) (CAT-8015-1004)
For: acute lymphoblastic leukemia (ALL), non-Hodgkin’s lymphoma (NHL), including lymphoblastic lymphoma, Burkitt’s lymphoma, and large cell lymphoma
A Phase II Study of Sunitinib (NSC# 736511, IND# 74019) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients - A Children’s Oncology Group (COG) Study (ACNS1021)
For: Recurrent, refractory or progressive glioma and ependymoma
A Phase II Randomized Trial of Lenalidomide (NSC#703813, IND#70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas
For: Recurrent, refractory or progressive brain tumors
Phase II Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors
For: Newly diagnosed localize primary NGGCT or newly diagnosed localized germinoma
A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High-Grade Gliomas
For: Newly diagnosed high grade gliomas
Phase III Randomized Trial of Maintenance Chemotherapy Versus Observation in Pediatric Patients (ages 1 to 21 yrs) With Newly Diagnosed Ependymoma Following Induction Chemotherapy and Post-Operative Radiation Therapy
For: Intracranial ependymoma
Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)
For: Diffuse intrinsic pontine gliomas
Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND study
For: Gene therapy: hepatic veno-occlusive disease
A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL (TACL protocol T2009-003)
For: Relapsed ALL
A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
For: Non-metastatic Ewing sarcoma
An Open-Label, Multi-Center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects with Confirmed Influenza Infection
For: Influenza
Low-dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial
For: For survivors of Hodgkin lymphoma
A Phase 2 Study of Ipilimumab in Children and adolescents (12 to < 18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
For: Previously treated or untreated, unresectable Stage III or Stage IV malignant melanoma
An Open-label, Multicenter, Single-arm, Phase I Dose-escalation with Efficacy Tail Extension study of R05185426 in Pediatric Patients with Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600
For: melanoma
A Phase I Pediatric Study of a Plerixafor Containing Regimen in Second Allogeneic Stem Cell Transplantation
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
For: Leukemia and other blood diseases
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide) in T-ALL Relapse: A Joint Study of TACL and POETIC
For: Leukemia
Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents
For: Human Immunodeficiency Virus
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
For: Relapsed acute lymphoblastic leukemia [ALL], acute myelogenous leukemia [AML], Hodgkin disease [HD] and non-Hodgkin’s lymphomas [NHL]
Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma/ Brain Tumor
For: Gliomas
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children with Recurrent or Refractory Medulloblastoma
For: Recurrent or refractory medulloblastoma
A Phase I /II Study of ABT-888, an Oral Poly (ADP-Ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, followed by ABT-888 and Temozolomide (TMZ), in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)
For: newly diagnosed diffuse intrinsic pontine gliomas (DIPG)
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil furamate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naïve Adolescents
For: HIV infections
Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy
For: Nasopharyngeal carcinoma
Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy
For: Adrenocortical tumors
Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor
For: Wilms tumor
Treatment for Patients with Bilateral, Multicentric, or Bilaterally- Predisposed Unilateral Wilms Tumor
For: Wilms tumor
Randomised Study Of First Time Immune Tolerance Induction In Patients With Severe Type A Haemophilia With Inhibitor At High Risk Of Failure: Comparison Of Induction Of Immune Tolerance With FVIII Concentrates With Or Without Von Willebrand Factor
For: Type A haemophilia
A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma
For: Extra-occular retinoblastoma
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)
For: Rhabdomyosarcoma
A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab[IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC # 742460]) inCombination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma
For: Rhabdomyosarcoma
A Randomized Phase II Trial of Bevacizumab (Avastin) and Temsirolimus (Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma
For: Recurrent or refractory rhabdomyosarcoma
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung
For: recurrent osteosarcoma
Sparing Conversion to Abnormal TCD Elevation (SCATE) - a Phase III clinical trial to compare standard care (observation) with alternative therapy (hydroxyurea) for reducing the risk of converting to an abnormal TCD velocity in children with sickle cell anemia and conditional pre-treatment TCD velocities
For: Sickle cell anemia
TCD with Transfusions Changing to Hydroxyurea (TWiTCH): A Phase III randomized clinical trial to compare standard therapy (erythrocyte transfusions) with alternative therapy (hydroxyurea) for the maintenance of lowered TCD velocities in pediatric subjects with sickle cell anemia and abnormal pre-treatment TCD velocities
For: Sickle cell disease
